Disease-A-Month
Volume 53, Issue 4 , Pages 206-213 , April 2007

Parkinson’s Disease in Women

References 

  1. In:  Kaplan PW editors. Neurologic Disease in Women. New York, NY: Demos Medical Publishing; 1998;
  2. Loy R, Gerlach J, McEwen BS. Autoradiographic localization of estradiol-binding neurons in the rat hippocampal formation and entorhinnal cortex. Brain Res. 1988;467:245–251
  3. Hagihara K, Hirata S, Osada T, et al. Distribution of cells containing progesterone receptor mRNA in the female rat di- and telencephalon: an in situ hybridization study. Mol Brain Res. 1992;14:239–249
  4. McEwen BS, Wooley CS. Estradiol and progesterone regulate neuronal structure and synaptic conductivity in adults as well as developing brain. Exp Gerontol. 1994;29:431–436
  5. Biegon A, Bercovitz H, Samuel D. Serotonin receptor concentration during the estrous cycle of the rat. Brain Res. 1980;187:221–225
  6. Becker JB. Direct effect of 17-Beta-estradiol on striatum sex differences in dopamine release. Synapse. 1990;5:157–164
  7. Sawada H, Ibi M, Kihara T, et al. Estradiol protects dopaminergic neurons in a MPP Parkinson’s disease model. Neuropharmacology. 2002;42:1056–1064
  8. Tao S, Shu-Leong H, Ramaden D. Estrogen can down-regulate the human catechol-O-methlytransferase gene expression: its implication in Parkinson’s disease. Mov Disord. 1998;13:114
  9. Bower JH, Maragonore DM, McDonnell SK, et al. Incidence and distribution of Parkinsonism in Olmstead County, Minnesota, 1976-1990. Neurology. 1999;52:1214–1220
  10. Benedetti MD, Maragonore DM, Bower JH, et al. Hysterectomy, menopause and estrogen use preceding Parkinson’s disease: an exploratory case-controlled study. Mov Disord. 2001;16:830–837
  11. Ragonese P, D’Amelio M, Salemi G, et al. Risk of Parkinson disease in women. Neurology. 2004;62:2010–2014
  12. Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the etiology of breast cancer. Lancet. 1969;1:604–609
  13. Melamed M, Castano E, Notides AC, et al. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11:1868–1878
  14. Kompoliti K, Comela CL, Jaglin JA, et al. Menstrual related changes in motoric function in women with Parkinson’s Disease. Neurology. 2000;55:1572–1574
  15. Quinn NP, Marsden DC. Menstrual related fluctuations in Parkinson’s Disease. Mov Disord. 1986;1:85–87
  16. Tolson D, Fleming V, Schartau E. Coping with menstruation: understanding the needs of women with Parkinson’s disease. J Adv Nurs. 2002;40:513–521
  17. Thulin PC, Carter JH, Nichols MD. Menstrual-cycle related changes in Parkinson’s disease. Neurology. 1996;46:128
  18. Roy S. Study on the relationship between Parkinson’s Disease and Women’s Health. 2000;Presentation to the Parkinson’s Disease Society, London. June, personal communication.
  19. Golbe L. Parkinson’s disease and pregnancy. Neurology. 1987;37:1245–1249
  20. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson’s disease: a review of the literature and a case report. Mov Disord. 1998;13:34–38
  21. Smith MSA, Evatt ML. Movement disorders in pregnancy. Neurol Clin. 2004;22:783–798
  22. Merchant CA, Cohen G, Mytilineou C, et al. Human transplacental transfer of carbidopa/levodopa. J Neural Trans. 1995;9:239–242
  23. Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson’s disease. Mov Disord. 2000;15:132–135
  24. Leranth C, Roth RH, Elswoth JD, et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson’s disease and memory. J Neurosci. 2000;20:8604–8609
  25. Disshon KA, Dluzen DE. Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female but not male rats. Brain Res. 2000;868:95–104
  26. Grandbois M, Morissette M, Callier S, et al. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Synapse. 2000;11:343–346
  27. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson’s disease with and without dementia. Neurology. 1998;50:1141–1143
  28. Fernandez HH, Lapane KL. Estrogen use among nursing home residents with a diagnosis of Parkinson’s disease. Mov Disord. 2000;15:1119–1124
  29. Harrison M, Currie L, Trugman J, et al. Effects of endogenous and exogenous estrogen on risk of Parkinson’s disease. Neurology. 2000;54:A444–A445
  30. Ascherio A, Chen H, Schwarzschild MA, et al. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology. 2003;60:790–795
  31. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord. 2001;16:830–837
  32. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000;54:2292–2298
  33. Saunders-Pullman R, Gordon-Elliott G, Parides M, et al. The effect of estrogen replacement on early Parkinson’s disease. Neurology. 1999;52:1417–1421

PII: S0011-5029(07)00005-3

doi: 10.1016/j.disamonth.2007.02.002

Disease-A-Month
Volume 53, Issue 4 , Pages 206-213 , April 2007

Article Tools